Predictors of Recurrence in Pediatric Perianal Abscess and Fistula-In-Ano: Insights From a 5-Year Surgical Cohort

Jakub Borkowski1, Zuzanna Zalewska1, Ewa Antonina Biegańska1

  • 1Department of Pediatric Surgery, Medical University of Warsaw, Warsaw, Poland.

Insights

Pediatric perianal abscess (PA) and fistula-in-ano (FIA) recurrence is higher when a fistula is found during surgery. Other factors like antibiotics or abscess size did not predict recurrence.

Area of Science:

  • Pediatric Surgery
  • Gastroenterology
  • Medical Imaging

Background:

  • Perianal abscess (PA) and fistula-in-ano (FIA) are common pediatric conditions with debated pathophysiology and treatment.
  • Optimal diagnostic and management strategies for pediatric PA and FIA require further investigation.

Purpose of the Study:

  • To evaluate recurrence rates after surgical treatment of pediatric PA and FIA.
  • To identify clinical factors associated with fistula formation and recurrence, including ultrasound findings, antibiotic therapy, abscess size, and symptom duration.

Main Methods:

  • Retrospective review of 108 pediatric patients (0-17 years) treated surgically for PA and/or FIA.
  • Data collected included intraoperative findings, recurrence, antibiotic use, ultrasound results, symptom duration, and abscess size.
  • Statistical analysis to identify factors associated with recurrence and fistula development.

Main Results:

  • Intraoperative fistula-in-ano (FIA) was identified in 17.8% of patients.
  • Overall recurrence occurred in 26.9% of patients, with significantly higher recurrence for FIA in those with initial FIA (31.6% vs 10.1%, P=0.024).
  • Ultrasound showed 100% diagnostic accuracy for PA, but variable accuracy for FIA. Antibiotic therapy, abscess size, and symptom duration did not significantly associate with recurrence.

Conclusions:

  • Initial intraoperative detection of FIA is a significant predictor of future recurrence in pediatric patients.
  • Antibiotic use, symptom duration, and abscess size were not found to be predictive of recurrence.
  • Improved diagnostic tools and standardized management protocols are needed for pediatric PA and FIA.

Related Concept Videos

5-Number Summary01:04

5-Number Summary

In a dataset, the 5-number summary includes the minimum data value, the data value of the first quartile, the median data value or data value of the second quartile, the data value of the third quartile, and the maximum data value. These 5 data values can be visualized as a box and whisker plot.
In a box plot, the minimum and maximum data values represent the lower and upper whiskers in the graph, and the median is designated as the center of the box in the chart. The first quartile and third...
5.5K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
276
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
200
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
261
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
626